What do you do when your patient doesn’t respond to your low-dose atropine treatment? This case explores the nuances in navigating management when atropine doesn’t work as well as you might expect.
Usually myopia and axial length are correlated. What does it mean when your patient has low myopia and high axial length? This case discusses various correlations between ocular and individual parameters and axial length.
How frequently should we measure axial length in myopia management practice, and how should it best direct our treatment strategy? Here we discuss how axial length change is related to refraction and ethnicity, and how to determine whether an axial length change is normal due to emmetropization or indicating myopia progression.
Low dose atropine is often used for myopia control in children. How commonly will patients complain of side effects, such as photophobia, allergy or blurry vision at near? BL presents a patient who experienced blurry vision after using 0.01% atropine once, and subsequently refused to use it. This led to significant fear and misconception on the part of the parent. How should a case like this be managed?
Given their lower efficacy compared to contact lens options, is the additional cost of a progressive or bifocal spectacle lens worth it for myopia control? This discussion in the Myopia Profile Facebook group explores the options, with links to further reading.
The research information on using atropine for myopia control is evolving. Previous research indicated 0.01% atropine was best, but newer research says otherwise. In this clinical case, practitioners discuss treatment strategies, which are put in research context with clinical pearls for practice.
A child has an allergic reaction to low dose atropine – or does he? Here practitioners consider the possible causes, with advice for management. We then frame this discussion in view of the evidence-base with take home clinical messages.
Read these three clinical complex atropine cases where general health conditions required careful consideration of atropine prescribing for myopia control.
When fitting orthokeratology for astigmatism, it is important to distinguish between refractive astigmatism and corneal toricity. Factors influencing the speed of response are also discussed.
MCS was hesitating fitting OrthoK to a patient who showed inferior corneal steepening. Her main concern was that OrthoK may induce corneal ecstasia/keratoconus in the future and whether there is a link between OrthoK and keratoconus.
